BenzingaAugust 12, 2026 at 8:18 AM NY23 days ago
Stephens & Co. Maintains Overweight on Amrize, Lowers Price Target to $54
Stephens & Co. analyst Trey Grooms maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $65 to $54.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Yahoo4 hours ago
Which dow jones stocks are moving on Friday?
ChartMill4 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill4 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo5 hours ago
Sector Update: Financial
Yahoo6 hours ago